Back to research

Research paper

mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing

Recent review of mTORopathy therapeutic landscape - rapalogs (rapamycin, everolimus), targeted gene editing, emerging precision therapies. mTOR inhibitors attenuate neuroinflammation in addition to seizure reduction, linking the mTORopathy and neuroinflammation mechanisms.

Indexed context

Boff MO, et al.

mtoropathypi3k-akt-mtorgene-editingrapamycineverolimusprecision-medicinereview

Markdown path

content/research/papers/2025-boff-mtoropathies-gene-editing-cells.md

Findings

Recent review of mTORopathy therapeutic landscape - rapalogs (rapamycin, everolimus), targeted gene editing, emerging precision therapies. mTOR inhibitors attenuate neuroinflammation in addition to seizure reduction, linking the mTORopathy and neuroinflammation mechanisms.

Why it may matter for Levi

Directly relevant to the leading mosaic PI3K-AKT-mTOR hypothesis. A confirmed molecular diagnosis in the mTOR axis would open actionable precision therapy (rapalogs FDA-approved in TSC; alpelisib approved for PROS). mTOR-pathway-driven neuroinflammation is consistent with Levi's April 2026 cytokine signature - mechanistically linking two of Levi's leading hypotheses. Gene editing is investigational and not a near-term option but worth long-horizon tracking.

Paper text

Boff et al. (2025) — mTORopathies in Epilepsy and Neurodevelopmental Disorders: Therapeutics and Gene Editing

Source

Why this paper is in the corpus

Recent review consolidating the mTORopathy therapeutic landscape — rapalogs (rapamycin, everolimus), targeted gene editing approaches, and emerging precision therapies. Updates and complements the 2021 Brain Communications mTORopathies review already in the corpus.

Key findings

  • Reviews the mTORopathy disease family: tuberous sclerosis complex, focal cortical dysplasia, PTEN / PIK3CA / AKT / mTOR-related overgrowth, and related conditions.
  • mTOR inhibitors (rapamycin, everolimus) reduce seizure frequency and attenuate neuroinflammation; already labeled for TSC-associated epilepsy.
  • Targeted gene-editing approaches (including CRISPR-based strategies) are emerging as a longer-term precision-therapy prospect for somatic mTOR-pathway variants.
  • Neuroinflammation is characterized as a reinforcing feature of mTORopathy epilepsy, consistent with the broader model that mTOR hyperactivation drives both neuronal dysfunction and immune activation.

Levi-relevant takeaways

  • Directly relevant to the leading mosaic PI3K-AKT-mTOR hypothesis in Levi's differential.
  • Reinforces that a confirmed molecular diagnosis in the mTOR axis would open an actionable precision-therapy path (rapalogs already FDA-approved in TSC; PIK3CA-specific alpelisib approved for PROS).
  • The paper's emphasis on mTOR-pathway-driven neuroinflammation is consistent with Levi's April 2026 Th1/Th17-weighted cytokine signature and with the 2016 van den Munckhof serum cytokine findings — mechanistically linking the mTOR hypothesis and the neuroinflammation hypothesis.
  • Gene editing remains investigational; not a near-term option for Levi, but worth tracking as a long-horizon possibility.

Citation note

Referenced as [23] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report. Related to 2021-mtoropathies-precision-medicine.md (earlier review) and 2024-lasser-pten-mtorc1-mtorc2.md (mechanistic paper).